Sonata Withdrawal and Tapering Help
How the Program and Tapering Process Works Sonata Dependence
Our Sonata weaning program is a slow taper that allows you to safely step down from Sonata under the guidance of our Prescription Experts; your Physician and Pharmacist.
The Pre-Taper is for Symptom Relief. You will not wean Sonata until you feel better. This is where our Advanced Nutraceuticals are critical.
Point of Return provides healthy, Drug-Free Strategies to help minimize Sonata withdrawal symptoms to improve mental and physical well-being.
Our areas of expertise are Antidepressants, Benzodiazepines, Sleeping Pills and Painkillers on a case-by-case basis.
At-Home programs are individualized based on your situation. An assessment is done once you start which allows us to individualize your gameplan based on age; length of time on the medications; health challenges; lifestyle, stress levels; additional medications; and interactions. Don't Wean Sonata alone, with with our Prescription Drug Experts. Start on your Point of Return today!
Imagine being Free of Sonata Addiction
- Proven Program completed At-Home with Expert Guidance
- Our secret is a Slow Taper combined with Powerful all-natural
Nutraceuticals to help ease Sonata withdrawal symptoms
- Your program is customized for your specific situation
- Professional information on interactions
- 15 years of experience helping people in 78 countries
- Free Expert Mentoring on our 24/7 private Discussion Board
- Free Assessment Upon Starting our Program (a $400 value)
Learn More about how our process works.
Break Free Today
At Point of Return, a 501(c)3 nonprofit, we have spent the last 15 years helping people come off sleeping pills correctly. With customized taper rates and all natural nutraceuticals, our program allows you to taper off Sonata, once and for all, from the comfort of your home.
Read program FAQs
Reach out for help
Sonata history and info
Sonata is a hypnotic that is prescribed for the treatment of insomnia.
Sonata should only be used short term due to the risk of tolerance, drug dependence, rebound insomnia and central nervous system related adverse effects. Once tolerance to the sleeping pill has occurred it is recommended to do a gradual dose reduction to minimize symptoms that resemble benzodiazepine withdrawal.
Sonata is a hypnotic that is prescribed for the treatment of insomnia. Although Sonata binds to the same family of receptors as benzodiazepines, it is considered a class of sedative drugs called cyclopyrrones, which are called nonbenzodiazepines.
Sleeping pills are classified as sedative hypnotics and work on receptors in the brain to slow down the nervous system to induce and maintain sleep. The newer medications do have a different chemical structure from a benzodiazepine, but they act more specifically in the same area of the brain on the Gamma-aminobutyric acid receptors (GABA). Therefore the hypnotic effects are similar to benzodiazepines even though sleeping pills are molecularly distinct. The term non-benzodiazepines was given to these new classes of sleeping pills, making many believe they will not experience dependence. But the warnings from the manufactures of zolpidem (Ambien) state, “Complex behaviors such as somnambulism, including driving or eating while not fully awake, with amnesia for the event, as well as abnormal behaviors such as being more outgoing or aggressive than normal, confusion, agitation and hallucinations may occur.” Continuous use is not recommended for more than 7--14 days. Similar warnings appear for all sleeping pills.
A trial performed by Dr. J.F. Pagel, a sleep physician at the University of Colorado Medical School, indicated that bizarre actions being committed while on sleeping pills are very prevalent. There have been 4 cases of
murder in which the defendant was found not guilty due to a blackout and subsequent amnesia while on sleeping pills.
According to the FDA:
You may have withdrawal symptoms when you stop taking SONATA. Withdrawal symptoms include unpleasant feelings, stomach and muscle cramps, vomiting, sweating, shakiness, and rarely seizures. You may also have more trouble sleeping the first few nights after Sonata is stopped. The problem usually goes away on its own after 1 or 2 nights.
Withdrawal-Emergent Anxiety and Insomnia
During nightly use for an extended period, pharmacodynamic tolerance or adaptation to some effects of hypnotics may develop. If the drug has a short elimination half-life, it is possible that a relative deficiency of the drug or its active metabolites (ie, in relationship to the receptor site) may occur at some point in the interval between each night's use. This sequence of events is believed to be responsible for two clinical findings reported to occur after several weeks of nightly use of other rapidly eliminated hypnotics: increased wakefulness during the last quarter of the night and the appearance of increased signs of daytime anxiety.
Zaleplon has a short half-life and no active metabolites. At the primary efficacy endpoint (nights 29 and 30) in a 35-night sleep laboratory study, polysomnographic recordings showed that wakefulness was not significantly longer with Sonata than with placebo during the last quarter of the night. No increase in the signs of daytime anxiety was observed in clinical trials with Sonata. In two sleep laboratory studies involving 14- and 28-nightly doses of Sonata (5 mg and 10 mg in one study and 10 mg and 20 mg in the second) and structured assessments of daytime anxiety, no increases in daytime anxiety were detected. Similarly, in a pooled analysis (all the parallel- group, placebo-controlled studies) of spontaneously reported daytime anxiety, no difference was observed between Sonata and placebo.
Rebound insomnia, defined as a dose-dependent temporary worsening in sleep parameters (latency, total sleep time, and number of awakenings) compared to baseline following discontinuation of treatment, is observed with short- and intermediate-acting hypnotics. Rebound insomnia following discontinuation of Sonata relative to baseline was examined at both nights 1 and 2 following discontinuation in three sleep laboratory studies (14, 28, and 35 nights) and five outpatient studies utilizing patient diaries (14 and 28 nights). Overall, the data suggest that rebound insomnia may be dose dependent. At 20 mg, there appeared to be both objective (polysomnographic) and subjective (diary) evidence of rebound insomnia on the first night after discontinuation of treatment with Sonata. At 5 mg and 10 mg, there was no objective and minimal subjective evidence of rebound insomnia on the first night after discontinuation of treatment with Sonata. At all doses, the rebound effect appeared to resolve by the second night following withdrawal. In the 35-night study, there was a worsening in sleep on the first night off for both the 10-mg and 20-mg groups compared to placebo, but not to baseline. This discontinuation-emergent effect was mild, had the characteristics of the return of the symptoms of chronic insomnia, and appeared to resolve by the second night after zaleplon discontinuation.
Other Withdrawal-Emergent Phenomena
The potential for other withdrawal phenomena was also assessed in 14- to 28-night studies, including both the sleep laboratory studies and the outpatient studies, and in open-label studies of 6- and 12-month durations. The Benzodiazepine Withdrawal Symptom Questionnaire was used in several of these studies, both at baseline and then during days 1 and 2 following discontinuation. Withdrawal was operationally defined as the emergence of 3 or more new symptoms after discontinuation. Sonata was not distinguishable from placebo at doses of 5 mg, 10 mg, or 20 mg on this measure, nor was Sonata distinguishable from placebo on spontaneously reported withdrawal-emergent adverse events. There were no instances of withdrawal delirium, withdrawal associated hallucinations, or any other manifestations of severe sedative/hypnotic withdrawal.
*While great care has been taken in organizing and presenting the material throughout this website, please note that it is provided for informational purposes only and should not be taken as Medical Advice.
*The statements on this website have not been evaluated by the Food and Drug Administration (FDA). The products and labels mentioned / sold are not intended to diagnose, treat, cure, or prevent any disease or illness.
* Testimonial results may vary person to person.
*The program outlined in Point of Return is not meant to substitute your doctor, instead it is to be utilized with your physician to help you with your drug withdrawal process and with his or her consent.
*Because prescription medications can cause severe withdrawal reactions, do not stop taking any medication without first consulting your physician. The decision to taper any medication should be discussed with your doctor and done with their consent and support. More...